Damm-Welk, ChristineChristineDamm-WelkSiddiqi, FarazFarazSiddiqiFischer, MatthiasMatthiasFischerHero, BarbaraBarbaraHeroNarayanan, VigneshVigneshNarayananCamidge, David RossDavid RossCamidgeHarris, MichaelMichaelHarrisBurke, AmosAmosBurkeLehrnbecher, ThomasThomasLehrnbecherPulford, KarenKarenPulfordOschlies, IlskeIlskeOschliesSiebert, ReinerReinerSiebertTurner, SuzanneSuzanneTurnerWoessmann, WilhelmWilhelmWoessmann2022-11-182018-11-272022-11-182016http://nbn-resolving.de/urn:nbn:de:hebis:26-opus-138808https://jlupub.ub.uni-giessen.de/handle/jlupub/9389http://dx.doi.org/10.22029/jlupub-8777Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.enNamensnennung - Nicht-kommerziell 4.0 InternationalALK-antibody titreNSCLCneuroblastomalymphomaddc:610